{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:25:11Z","timestamp":1790324711507,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1007\/s11892-005-0050-z","type":"journal-article","created":{"date-parts":[[2007,5,19]],"date-time":"2007-05-19T23:18:56Z","timestamp":1179616736000},"page":"430-435","source":"Crossref","is-referenced-by-count":55,"title":["Theories concerning the pathogenesis of the acute Charcot foot suggest future therapy"],"prefix":"10.1007","volume":"5","author":[{"given":"William J.","family":"Jeffcoate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"50_CR1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.1464-5491.2000.00233.x","volume":"17","author":"W Jeffcoate","year":"2000","unstructured":"Jeffcoate W, Lima J, Nobrega L: The Charcot foot. Diabet Med 2000, 17:253\u2013258.","journal-title":"Diabet Med"},{"key":"50_CR2","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00125-002-0885-7","volume":"45","author":"SM Rajbhandari","year":"2002","unstructured":"Rajbhandari SM, Jenkins RC, Davies C, Tesfaye S: Charcot neuroarthropathy in diabetes mellitus. Diabetologia 2002, 45:1085\u20131096.","journal-title":"Diabetologia"},{"key":"50_CR3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1464-5491.1991.tb01517.x","volume":"8","author":"JD Nabarro","year":"1991","unstructured":"Nabarro JD: Diabetes in the United Kingdom: a personal series. Diabet Med 1991, 8:59\u201368.","journal-title":"Diabet Med"},{"key":"50_CR4","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2337\/diacare.23.6.796","volume":"23","author":"J Fabrin","year":"2000","unstructured":"Fabrin J, Larsen K, Holstein PE: Long-term follow-up in diabetic Charcot feet with spontaneous onset. Diabetes Care 2000, 23:796\u2013800.","journal-title":"Diabetes Care"},{"key":"50_CR5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00003086-200506000-00026","volume":"435","author":"CL Saltzman","year":"2005","unstructured":"Saltzman CL, Hagy ML, Zimmerman B, et al.: How effective is intensive nonoperative initial treatment of patients with diabetes and Charcot arthropathy of the feet? Clin Orthop Relat Res 2005, 435:185\u2013190.","journal-title":"Clin Orthop Relat Res"},{"key":"50_CR6","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2519\/jospt.1999.29.12.736","volume":"29","author":"DR Sinacore","year":"1999","unstructured":"Sinacore DR, Withrington NC: Recognition and management of acute neuropathic (Charcot) arthropathies of the foot and ankle. J Orthop Sports Phys Ther 1999, 29:736\u2013746.","journal-title":"J Orthop Sports Phys Ther"},{"key":"50_CR7","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1464-5491.2004.01215.x","volume":"21","author":"A Gazis","year":"2004","unstructured":"Gazis A, Pound N, Macfarlane R, et al.: Mortality in patients with diabetic neuropathic osteoarthropathy (Charcot foot). Diabet Med 2004, 21:1243\u20131246.","journal-title":"Diabet Med"},{"key":"50_CR8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00000441-183108150-00004","volume":"8","author":"JK Mitchell","year":"1831","unstructured":"Mitchell JK: On a new practice in acute and chronic rheumatism. Am J Med Sci 1831, 8:55\u201364.","journal-title":"Am J Med Sci"},{"key":"50_CR9","first-page":"161","volume":"1","author":"JM Charcot","year":"1868","unstructured":"Charcot JM: Sur quelques arthropathies qui paraissent d\u00e9pendre d\u2019une l\u00e9sion cerveau ou de la mouelle \u00e9pini\u00e8re. Arch Physiol Norm Pathol 1868, 1:161\u2013178.","journal-title":"Arch Physiol Norm Pathol"},{"key":"50_CR10","first-page":"305","volume":"6","author":"JM Charcot","year":"1883","unstructured":"Charcot JM, F\u00e9r\u00e9 C: Affections osseuses et articulaires du pied chez les tab\u00e9tiques (pied tab\u00e9tique). Arch Neurol 1883, 6:305\u2013309.","journal-title":"Arch Neurol"},{"key":"50_CR11","unstructured":"Transaction of the International Medical Congress [no authors listed]. 1881, 8:128\u2013129."},{"key":"50_CR12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/archinte.1936.00170060069004","volume":"57","author":"WR Jordan","year":"1936","unstructured":"Jordan WR: Neuritic manifestations in diabetes mellitus. Arch Intern Med 1936, 57:307\u2013366.","journal-title":"Arch Intern Med"},{"key":"50_CR13","unstructured":"Berliner medicinische Gesellschaft [no authors listed]. Sitzung vom 17 November. Berliner Klinische Wonchenschr 1886."},{"key":"50_CR14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00402547","volume":"35","author":"MJ Stevens","year":"1992","unstructured":"Stevens MJ, Edmonds ME, Foster AV, Watkins PJ: Selective neuropathy and preserved vascular responses in the diabetic Charcot foot. Diabetologia 1992, 35:148\u2013154.","journal-title":"Diabetologia"},{"key":"50_CR15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2337\/diacare.18.1.34","volume":"18","author":"MJ Young","year":"1995","unstructured":"Young MJ, Marshall A, Adams JE, et al.: Osteopenia, neurological dysfunction, and the development of Charcot neuroarthropathy. Diabetes Care 1995, 18:34\u201338.","journal-title":"Diabetes Care"},{"key":"50_CR16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/path.1700100302","volume":"10","author":"VE Henderson","year":"1905","unstructured":"Henderson VE: Joint affectations in tabes dorsalis. J Pathol 1905, 10:211\u2013263.","journal-title":"J Pathol"},{"key":"50_CR17","first-page":"1022","volume":"53","author":"R Leriche","year":"1927","unstructured":"Leriche R: Sur quelques maladies osseuses et articulaires d\u2019origine vaso-motrice et sur leur traitement. Bull Mem Soc Nat Chir 1927, 53:1022\u20131030.","journal-title":"Bull Mem Soc Nat Chir"},{"key":"50_CR18","first-page":"178","volume":"132","author":"G Marinescu","year":"1937","unstructured":"Marinescu G, Bruch H: Zur kenntnis der gelenkst\u00fcrungen bei tabes. Zeitschr F Klin Med 1937, 132:178\u2013182.","journal-title":"Zeitschr F Klin Med"},{"key":"50_CR19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archneurpsyc.1947.02300250051004","volume":"57","author":"DB Foster","year":"1947","unstructured":"Foster DB, Bassett RC: Neurogenic arthropathy associated with (Charcot joint) with diabetic neuropathy: report of two cases. Arch Neurol Psychiat 1947, 57:173\u2013185.","journal-title":"Arch Neurol Psychiat"},{"key":"50_CR20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/003591575204500813","volume":"45","author":"MM Martin","year":"1952","unstructured":"Martin MM: Charcot joints in diabetes mellitus. Proc Roy Soc Med 1952, 45:503\u2013506.","journal-title":"Proc Roy Soc Med"},{"key":"50_CR21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0140-6736(53)91693-6","volume":"1","author":"MM Martin","year":"1953","unstructured":"Martin MM: Involvement of autonomic nerve fibres in diabetic neuropathy. Lancet 1953, 1:560\u2013565.","journal-title":"Lancet"},{"key":"50_CR22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/BF00276968","volume":"27","author":"AG Archer","year":"1984","unstructured":"Archer AG, Roberts VC, Watkins PJ: Blood flow patterns in diabetic neuropathy. Diabetologia 1984, 27:563\u2013567.","journal-title":"Diabetologia"},{"key":"50_CR23","first-page":"90","volume":"26","author":"R Ziegler","year":"1992","unstructured":"Ziegler R: Diabetes mellitus and bone metabolism. Horm Metab Res Suppl 1992, 26:90\u201394.","journal-title":"Horm Metab Res Suppl"},{"key":"50_CR24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1464-5491.1985.tb00683.x","volume":"2","author":"T Cundy","year":"1985","unstructured":"Cundy T, Edmonds ME, Watkins PJ: Osteopenia and metatarsal fractures in diabetic neuropathy. Diabet Med 1985, 2:461\u2013464.","journal-title":"Diabet Med"},{"key":"50_CR25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/1056-8727(94)90058-2","volume":"8","author":"MJ Kayath","year":"1994","unstructured":"Kayath MJ, Dib SA, Vieia JG: Prevalence and magnitude of osteopenia associated with insulin-dependent diabetes mellitus. J Diabet Complications 1994, 8:97\u2013104.","journal-title":"J Diabet Complications"},{"key":"50_CR26","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1007\/s00125-004-1477-5","volume":"47","author":"W Jeffcoate","year":"2004","unstructured":"Jeffcoate W: Vascular calcification and osteolysis in diabetic neuropathy\u2014is RANK-L the missing link ? Diabetologia 2004, 47:1488\u20131492. Reviews the evidence suggesting the importance of the OPG\/RANKL signaling pathway in diabetic neuropathy, and includes speculation on possible mechanisms underlying abnormal activation of NF-\u043aB in type 1 and type 2 diabetes, with and without nerve damage.","journal-title":"Diabetologia"},{"key":"50_CR27","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1464-5491.1995.tb00389.x","volume":"12","author":"T Forst","year":"1995","unstructured":"Forst T, Pfutzner A, Kann P, et al.: Peripheral osteopenia in adult patients with insulin-dependent diabetes mellitus. Diabet Med 1995, 12:874\u2013879.","journal-title":"Diabet Med"},{"key":"50_CR28","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2337\/diacare.22.5.827","volume":"22","author":"M Rix","year":"1999","unstructured":"Rix M, Andresaasen H, Eskilden P: Impact of peripheral neuropathy on bone density in patients with type 1 diabetes. Diabetes Care 1999, 22:827\u2013831.","journal-title":"Diabetes Care"},{"key":"50_CR29","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1464-5491.2005.01510.x","volume":"22","author":"NL Petrova","year":"2005","unstructured":"Petrova NL, Foster AV, Edmonds ME: Calcaneal bone mineral density in patients with Charcot neuropathic osteoarthropathy: differences between type 1 and type 2 diabetes. Diabet Med 2005, 22:756\u2013761.","journal-title":"Diabet Med"},{"key":"50_CR30","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1302\/0301-620X.86B3.14593","volume":"86","author":"SA Herbst","year":"2004","unstructured":"Herbst SA, Jones KB, Saltzman CL: Pattern of diabetic neuropathic osteoarthropathy associated with the peripheral bone mineral density. J Bone Joint Surg Br 2004, 86:378\u2013383.","journal-title":"J Bone Joint Surg Br"},{"key":"50_CR31","first-page":"2355","volume":"85","author":"LC Hofbauer","year":"2005","unstructured":"Hofbauer LC, Heufelder AE: The role of receptor activator of nuclear factor kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 2005, 85:2355\u20132363.","journal-title":"J Clin Endocrinol Metab"},{"key":"50_CR32","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1210\/endo.142.12.8536","volume":"142","author":"S Khosla","year":"2001","unstructured":"Khosla S: Minireview: the OPG\/RANKL\/RANK system. Endocrinology 2001, 142:5050\u20135055.","journal-title":"Endocrinology"},{"key":"50_CR33","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/01.ATV.0000012303.37971.DA","volume":"22","author":"M Schoppet","year":"2002","unstructured":"Schoppet M, Preissner KT, Hofbauer LC: RANK ligand and osteoprotegerin. Paracrine regulators of bone metabolism and vascular function. Arterioscl Thromb Vasc Biol 2002, 22:549\u2013553.","journal-title":"Arterioscl Thromb Vasc Biol"},{"key":"50_CR34","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(03)01076-3","volume":"4","author":"AJ Ashcroft","year":"2003","unstructured":"Ashcroft AJ, Davies FE, Morgan GJ: Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol 2003, 4:284\u2013292.","journal-title":"Lancet Oncol"},{"key":"50_CR35","doi-asserted-by":"crossref","unstructured":"Rogers A, Eastell R: Circulating osteoprotegerin (OPG) and receptor activator for NFkappaB ligand (RANKL): clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005, Aug 16; [Epub ahead of print]. An up-to-date review of current knowledge of the role of the OPG\/RANKL signaling pathway in bone.","DOI":"10.1210\/jc.2005-0794"},{"key":"50_CR36","first-page":"631","volume":"86","author":"WS Browner","year":"2001","unstructured":"Browner WS, Lui LY, Cummings SR: Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001, 86:631\u2013637.","journal-title":"J Clin Endocrinol Metab"},{"key":"50_CR37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1530\/eje.0.1490039","volume":"149","author":"ST Knudsen","year":"2003","unstructured":"Knudsen ST, Foss CH, Poulsen PL, et al.: Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003, 149:39\u201342.","journal-title":"Eur J Endocrinol"},{"key":"50_CR38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.diabres.2004.08.006","volume":"68","author":"K Suzuki","year":"2005","unstructured":"Suzuki K, Kurose T, Takizawa M, et al.: Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor\/ osteoprotegerin (OCIF\/OPG) on the decrease off bone mineral density. Diabetes Res Clin Pract 2005, 68:117\u2013125.","journal-title":"Diabetes Res Clin Pract"},{"key":"50_CR39","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1136\/bmj.284.6320.928","volume":"284","author":"ME Edmonds","year":"1982","unstructured":"Edmonds ME, Morrison N, Laws JW, Watkins PJ: Medial arterial calcification and diabetic neuropathy. BMJ 1982, 284:928\u2013930.","journal-title":"BMJ"},{"key":"50_CR40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF00251822","volume":"24","author":"FD Goebel","year":"1983","unstructured":"Goebel FD, Fuessl HS: Monckeberg\u2019s sclerosis after sympathetic denervation in diabetic and non-diabetic subjects. Diabetologia 1983, 24:347\u2013350.","journal-title":"Diabetologia"},{"key":"50_CR41","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/00005792-197205000-00006","volume":"51","author":"S Sinha","year":"1972","unstructured":"Sinha S, Munichoodappa C, Kozak GP: Neuro-arthropathy (Charcot joints) in diabetes mellitus: a clinical study of 101 cases. Medicine (Baltimore) 1972, 51:191\u2013210.","journal-title":"Medicine (Baltimore)"},{"key":"50_CR42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2214\/ajr.121.1.22","volume":"121","author":"ME Clouse","year":"1974","unstructured":"Clouse ME, Gramm HF, Legg M, Flood T: Diabetic osteoarthropathy: clinical and roentgenographic observations in 90 cases. AJR Am J Roentgenol 1974, 121:22\u201333.","journal-title":"AJR Am J Roentgenol"},{"key":"50_CR43","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/pdi.1960130309","volume":"13","author":"TS Purewal","year":"1996","unstructured":"Purewal TS: Charcot\u2019s diabetic neuroarthropathy: pathogenesis, diagnosis and management. Pract Diab Int 1996, 13:88\u201391.","journal-title":"Pract Diab Int"},{"key":"50_CR44","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","volume":"1","author":"N Bucay","year":"1998","unstructured":"Bucay N, Sarosi I, Dunstan CR, et al.: Osteoprotegerindeficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 1:1260\u20131268.","journal-title":"Genes Dev"},{"key":"50_CR45","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(01)05494-0","volume":"358","author":"LC Hofbauer","year":"2001","unstructured":"Hofbauer LC, Schoppet M: Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet 2001, 358:257\u2013259.","journal-title":"Lancet"},{"key":"50_CR46","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/00041552-200207000-00011","volume":"11","author":"LL Demer","year":"2002","unstructured":"Demer LL, Tintut Y, Parhami F: Novel mechanisms in accelerated vascular calcification in renal disease patients. Curr Opin Nephrol Hypertens 2002, 11:437\u2013443.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"50_CR47","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1210\/jc.2003-031432","volume":"89","author":"M Schoppet","year":"2004","unstructured":"Schoppet M, Al-Fakhari N, Franke FE, et al.: Localization of osteoprotegerin, tumor necrosis factor-related apoptosisinducing ligand, and receptor activator of nuclear factorkappaB ligand in M\u00f6nckeberg\u2019s sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004, 89:4101\u20134112.","journal-title":"J Clin Endocrinol Metab"},{"key":"50_CR48","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/01.RES.0000149165.99974.12","volume":"95","author":"F Collin-Osdoby","year":"2004","unstructured":"Collin-Osdoby F: Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004, 95:1046\u20131057.","journal-title":"Circ Res"},{"key":"50_CR49","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00198-003-1550-9","volume":"15","author":"P Pennisi","year":"2004","unstructured":"Pennisi P, Signorelli SS, Riccobene S, et al.: Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporosis Int 2004, 15:389\u2013395.","journal-title":"Osteoporosis Int"},{"key":"50_CR50","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1001\/archinte.1987.00370080142027","volume":"147","author":"SV Edelman","year":"1987","unstructured":"Edelman SV, Kosofsky EM, Paul RA, Kozak GP: Neuro-arthropathy (Charcot\u2019s joints) in diabetes mellitus following revascularisation surgery. Arch Intern Med 1987, 147:1504\u20131508.","journal-title":"Arch Intern Med"},{"key":"50_CR51","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/107110079902000203","volume":"20","author":"JE Fleischli","year":"1999","unstructured":"Fleischli JE, Anderson RB, Davis WH: Dorsiflexion metatarsal osteotomy for treatment of recalcitrant diabetic neuropathic ulcers. Foot Ankle Int 1999, 20:80\u201385.","journal-title":"Foot Ankle Int"},{"key":"50_CR52","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1359\/jbmr.2003.18.9.1584","volume":"18","author":"LC Gerstenfeld","year":"2003","unstructured":"Gerstenfeld LC, Cho TJ, Kon T, et al.: Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption. J Bone Miner Res 2003, 18:1584\u20131592.","journal-title":"J Bone Miner Res"},{"key":"50_CR53","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S8756-3282(99)00162-3","volume":"25","author":"LC Hofbauer","year":"1999","unstructured":"Hofbauer LC, Lacey DL, Dunstan CR, et al.: Interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999, 25:255\u2013259.","journal-title":"Bone"},{"key":"50_CR54","first-page":"144","volume":"13","author":"N Saidenberg-Kermanac\u2019h","year":"2002","unstructured":"Saidenberg-Kermanac\u2019h N, Bessis N, Cohen-Salal M, et al.: Osteoprotegerin and inflammation. Eur Cytokine Netw 2002, 13:144\u2013153.","journal-title":"Eur Cytokine Netw"},{"issue":"suppl 2","key":"50_CR55","doi-asserted-by":"crossref","first-page":"ii82","DOI":"10.1136\/ard.61.suppl_2.ii82","volume":"61","author":"J Lam","year":"2002","unstructured":"Lam J, Abu-Amer Y, Nelson, et al.: Tumour necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis. Ann Rheum Dis 2002, 61(suppl 2):ii82-ii83.","journal-title":"Ann Rheum Dis"},{"key":"50_CR56","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1359\/jbmr.2001.16.6.1004","volume":"16","author":"T Kon","year":"2001","unstructured":"Kon T, Cho TJ, Aizawa T, et al.: Expression of osteoprotegerin, receptor-activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. J Bone Miner Res 2001, 16:1004\u20131014.","journal-title":"J Bone Miner Res"},{"key":"50_CR57","doi-asserted-by":"crossref","unstructured":"Jeffcoate WJ, Game F, Cavanagh PR: The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 2005, Aug 10; [Epub ahead of print]. This hypothesis outlines the evidence to suggest a central role on inflammation in the development of the acute Charcot foot.","DOI":"10.1016\/S0140-6736(05)67029-8"},{"key":"50_CR58","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1056-8727(97)00080-9","volume":"12","author":"SA Shapiro","year":"1998","unstructured":"Shapiro SA, Stansberry KB, Hill MA, et al.: Normal blood flow response and vasomotion in the diabetic foot. J Diabetes Complications 1998, 12:147\u2013153.","journal-title":"J Diabetes Complications"},{"key":"50_CR59","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/toxsci\/kfi002","volume":"82","author":"DS Perrien","year":"2004","unstructured":"Perrien DS, Wahl EC, Hogue WR, et al.: IL-1 and TNF antagonists prevent inhibition of fracture healing by ethanol in rats. Toxicol Sci 2004, 82:656\u2013660.","journal-title":"Toxicol Sci"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-005-0050-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-005-0050-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-005-0050-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T22:50:01Z","timestamp":1683845401000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-005-0050-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["50"],"URL":"https:\/\/doi.org\/10.1007\/s11892-005-0050-z","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}